O	0	8	OlympiAD
O	9	14	final
O	15	22	overall
O	23	31	survival
O	32	35	and
O	36	48	tolerability
O	49	56	results
O	56	57	:
B-intervention	58	66	Olaparib
O	67	73	versus
B-control	74	86	chemotherapy
I-control	87	96	treatment
O	97	99	of
O	100	109	physician
O	109	110	'
O	110	111	s
O	112	118	choice
O	119	121	in
O	122	130	patients
O	131	135	with
O	136	137	a
O	138	146	germline
O	147	151	BRCA
O	152	160	mutation
O	161	164	and
O	165	169	HER2
O	169	170	-
O	170	178	negative
O	179	189	metastatic
O	190	196	breast
O	197	203	cancer
O	203	204	.

O	205	207	In
O	208	211	the
O	212	220	OlympiAD
O	221	226	study
O	226	227	,
O	228	236	olaparib
O	237	240	was
O	241	246	shown
O	247	249	to
O	250	257	improve
O	258	269	progression
O	269	270	-
O	270	274	free
O	275	283	survival
O	284	292	compared
O	293	297	with
O	298	310	chemotherapy
O	311	320	treatment
O	321	323	of
O	324	333	physician
O	333	334	'
O	334	335	s
O	336	342	choice
O	343	344	(
O	344	347	TPC
O	347	348	)
O	349	351	in
O	352	360	patients
O	361	365	with
O	366	367	a
O	368	376	germline
O	377	382	BRCA1
O	383	386	and
O	386	387	/
O	387	389	or
O	390	395	BRCA2
O	396	404	mutation
O	405	406	(
O	406	411	BRCAm
O	411	412	)
O	413	416	and
O	417	422	human
O	423	432	epidermal
O	433	439	growth
O	440	446	factor
O	447	455	receptor
O	456	457	2
O	458	459	(
O	459	463	HER2
O	463	464	)
O	464	465	-
O	465	473	negative
O	474	484	metastatic
O	485	491	breast
O	492	498	cancer
O	499	500	(
O	500	503	mBC
O	503	504	)
O	504	505	.

O	506	508	We
O	509	512	now
O	513	519	report
O	520	523	the
O	524	531	planned
O	532	537	final
O	538	545	overall
O	546	554	survival
O	555	556	(
O	556	558	OS
O	558	559	)
O	560	567	results
O	567	568	,
O	569	572	and
O	573	581	describe
O	582	585	the
O	586	590	most
O	591	597	common
O	598	605	adverse
O	606	612	events
O	613	614	(
O	614	617	AEs
O	617	618	)
O	619	621	to
O	622	628	better
O	629	639	understand
O	640	648	olaparib
O	649	661	tolerability
O	662	664	in
O	665	669	this
O	670	680	population
O	680	681	.

O	682	690	OlympiAD
O	690	691	,
O	692	693	a
O	694	699	Phase
O	700	703	III
O	703	704	,
O	705	715	randomized
O	715	716	,
O	717	727	controlled
O	727	728	,
O	729	733	open
O	733	734	-
O	734	739	label
O	740	745	study
O	746	747	(
O	747	758	NCT02000622
O	758	759	)
O	759	760	,
B-eligibility	761	769	enrolled
I-eligibility	770	778	patients
I-eligibility	779	783	with
I-eligibility	784	785	a
I-eligibility	786	794	germline
I-eligibility	795	800	BRCAm
I-eligibility	801	804	and
I-eligibility	805	809	HER2
I-eligibility	809	810	-
I-eligibility	810	818	negative
I-eligibility	819	822	mBC
I-eligibility	823	826	who
I-eligibility	827	830	had
I-eligibility	831	839	received
I-eligibility	840	841	â‰¤
I-eligibility	841	842	2
I-eligibility	843	848	lines
I-eligibility	849	851	of
I-eligibility	852	864	chemotherapy
I-eligibility	865	868	for
I-eligibility	869	872	mBC
O	872	873	.

O	874	882	Patients
O	883	887	were
O	888	898	randomized
O	899	901	to
O	902	910	olaparib
O	911	918	tablets
O	919	920	(
O	920	923	300
O	924	926	mg
O	927	930	bid
O	930	931	)
O	932	934	or
O	935	946	predeclared
O	947	950	TPC
O	951	952	(
O	952	964	capecitabine
O	964	965	,
O	966	977	vinorelbine
O	977	978	,
O	979	981	or
O	982	990	eribulin
O	990	991	)
O	991	992	.

B-outcome-Measure	993	995	OS
O	996	999	and
B-outcome-Measure	1000	1006	safety
O	1007	1011	were
O	1012	1021	secondary
O	1022	1025	end
O	1026	1032	points
O	1032	1033	.

O	1034	1035	A
O	1036	1041	total
O	1042	1044	of
B-intervention-participants	1045	1048	205
O	1049	1057	patients
O	1058	1062	were
O	1063	1073	randomized
O	1074	1076	to
O	1077	1085	olaparib
O	1086	1089	and
B-control-participants	1090	1092	97
O	1093	1095	to
O	1096	1099	TPC
O	1099	1100	.

O	1101	1103	At
O	1104	1106	64
O	1106	1107	%
O	1108	1112	data
O	1113	1121	maturity
O	1121	1122	,
B-outcome	1123	1129	median
I-outcome	1130	1132	OS
O	1133	1136	was
B-iv-cont-median	1137	1139	19
I-iv-cont-median	1139	1140	.
I-iv-cont-median	1140	1141	3
I-iv-cont-median	1142	1148	months
O	1149	1153	with
O	1154	1162	olaparib
O	1163	1169	versus
B-cv-cont-median	1170	1172	17
I-cv-cont-median	1172	1173	.
I-cv-cont-median	1173	1174	1
I-cv-cont-median	1175	1181	months
O	1182	1186	with
O	1187	1190	TPC
O	1191	1192	(
O	1192	1194	HR
O	1195	1196	0
O	1196	1197	.
O	1197	1199	90
O	1199	1200	,
O	1201	1203	95
O	1203	1204	%
O	1205	1207	CI
O	1208	1209	0
O	1209	1210	.
O	1210	1212	66
O	1212	1213	-
O	1213	1214	1
O	1214	1215	.
O	1215	1217	23
O	1217	1218	;
O	1219	1220	P
O	1221	1222	=
O	1223	1224	0
O	1224	1225	.
O	1225	1228	513
O	1228	1229	)
O	1229	1230	;
O	1231	1237	median
O	1238	1244	follow
O	1244	1245	-
O	1245	1247	up
O	1248	1251	was
O	1252	1254	25
O	1254	1255	.
O	1255	1256	3
O	1257	1260	and
O	1261	1263	26
O	1263	1264	.
O	1264	1265	3
O	1266	1272	months
O	1272	1273	,
O	1274	1286	respectively
O	1286	1287	.

O	1288	1290	HR
O	1291	1294	for
O	1295	1297	OS
O	1298	1302	with
O	1303	1311	olaparib
O	1312	1318	versus
O	1319	1322	TPC
O	1323	1325	in
O	1326	1338	prespecified
O	1339	1348	subgroups
O	1349	1353	were
O	1353	1354	:
B-outcome	1355	1360	prior
I-outcome	1361	1373	chemotherapy
I-outcome	1374	1377	for
I-outcome	1378	1381	mBC
O	1382	1383	[
O	1383	1385	no
O	1386	1387	(
O	1387	1392	first
O	1392	1393	-
O	1393	1397	line
O	1398	1405	setting
O	1405	1406	)
O	1406	1407	:
O	1408	1409	0
O	1409	1410	.
O	1410	1412	51
O	1412	1413	,
O	1414	1416	95
O	1416	1417	%
O	1418	1420	CI
O	1421	1422	0
O	1422	1423	.
O	1423	1425	29
O	1425	1426	-
O	1426	1427	0
O	1427	1428	.
O	1428	1430	90
O	1430	1431	;
O	1432	1435	yes
O	1436	1437	(
O	1437	1443	second
O	1443	1444	/
O	1444	1449	third
O	1449	1450	-
O	1450	1454	line
O	1454	1455	)
O	1455	1456	:
O	1457	1458	1
O	1458	1459	.
O	1459	1461	13
O	1461	1462	,
O	1463	1464	0
O	1464	1465	.
O	1465	1467	79
O	1467	1468	-
O	1468	1469	1
O	1469	1470	.
O	1470	1472	64
O	1472	1473	]
O	1473	1474	;
B-outcome	1475	1483	receptor
I-outcome	1484	1490	status
O	1491	1492	(
O	1492	1498	triple
O	1499	1507	negative
O	1507	1508	:
O	1509	1510	0
O	1510	1511	.
O	1511	1513	93
O	1513	1514	,
O	1515	1516	0
O	1516	1517	.
O	1517	1519	62
O	1519	1520	-
O	1520	1521	1
O	1521	1522	.
O	1522	1524	43
O	1524	1525	;
O	1526	1533	hormone
O	1534	1542	receptor
O	1543	1551	positive
O	1551	1552	:
O	1553	1554	0
O	1554	1555	.
O	1555	1557	86
O	1557	1558	,
O	1559	1560	0
O	1560	1561	.
O	1561	1563	55
O	1563	1564	-
O	1564	1565	1
O	1565	1566	.
O	1566	1568	36
O	1568	1569	)
O	1569	1570	;
B-outcome	1571	1576	prior
I-outcome	1577	1585	platinum
O	1586	1587	(
O	1587	1590	yes
O	1590	1591	:
O	1592	1593	0
O	1593	1594	.
O	1594	1596	83
O	1596	1597	,
O	1598	1599	0
O	1599	1600	.
O	1600	1602	49
O	1602	1603	-
O	1603	1604	1
O	1604	1605	.
O	1605	1607	45
O	1607	1608	;
O	1609	1611	no
O	1611	1612	:
O	1613	1614	0
O	1614	1615	.
O	1615	1617	91
O	1617	1618	,
O	1619	1620	0
O	1620	1621	.
O	1621	1623	64
O	1623	1624	-
O	1624	1625	1
O	1625	1626	.
O	1626	1628	33
O	1628	1629	)
O	1629	1630	.

B-outcome	1631	1638	Adverse
I-outcome	1639	1645	events
O	1646	1652	during
O	1653	1661	olaparib
O	1662	1671	treatment
O	1672	1676	were
O	1677	1686	generally
O	1687	1690	low
O	1691	1696	grade
O	1697	1700	and
O	1701	1711	manageable
O	1712	1714	by
O	1715	1725	supportive
O	1726	1735	treatment
O	1736	1738	or
O	1739	1743	dose
O	1744	1756	modification
O	1756	1757	.

O	1758	1763	There
O	1764	1767	was
O	1768	1769	a
O	1770	1773	low
B-outcome	1774	1778	rate
I-outcome	1779	1781	of
I-outcome	1782	1791	treatment
I-outcome	1792	1807	discontinuation
O	1808	1809	(
O	1809	1810	4
O	1810	1811	.
O	1811	1812	9
O	1812	1813	%
O	1813	1814	)
O	1814	1815	,
O	1816	1819	and
O	1820	1823	the
O	1824	1828	risk
O	1829	1831	of
O	1832	1842	developing
B-outcome	1843	1849	anemia
O	1850	1853	did
O	1854	1857	not
O	1858	1866	increase
O	1867	1871	with
O	1872	1880	extended
O	1881	1889	olaparib
O	1890	1898	exposure
O	1898	1899	.

O	1900	1905	While
O	1906	1911	there
O	1912	1915	was
O	1916	1918	no
O	1919	1932	statistically
O	1933	1944	significant
O	1945	1956	improvement
O	1957	1959	in
O	1960	1962	OS
O	1963	1967	with
O	1968	1976	olaparib
O	1977	1985	compared
O	1986	1988	to
O	1989	1992	TPC
O	1992	1993	,
O	1994	1999	there
O	2000	2003	was
O	2004	2007	the
O	2008	2019	possibility
O	2020	2022	of
O	2023	2033	meaningful
O	2034	2036	OS
O	2037	2044	benefit
O	2045	2050	among
O	2051	2059	patients
O	2060	2063	who
O	2064	2067	had
O	2068	2071	not
O	2072	2080	received
O	2081	2093	chemotherapy
O	2094	2097	for
O	2098	2108	metastatic
O	2109	2116	disease
O	2116	2117	.

O	2118	2126	Olaparib
O	2127	2130	was
O	2131	2140	generally
O	2141	2145	well
O	2145	2146	-
O	2146	2155	tolerated
O	2155	2156	,
O	2157	2161	with
O	2162	2164	no
O	2165	2173	evidence
O	2174	2176	of
O	2177	2187	cumulative
O	2188	2196	toxicity
O	2197	2203	during
O	2204	2212	extended
O	2213	2221	exposure
O	2221	2222	.

O	2223	2229	Please
O	2230	2233	see
O	2234	2237	the
O	2238	2245	article
O	2246	2252	online
O	2253	2256	for
O	2257	2267	additional
O	2268	2273	video
O	2274	2281	content
O	2281	2282	.
